.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Federal Trade Commission
Farmers Insurance
US Department of Justice
Teva
Baxter
Healthtrust
QuintilesIMS
Daiichi Sankyo

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,718,619 protect, and when does it expire?


Patent ► Subscribe protects VYVANSE and is included in two NDAs. There has been one Paragraph IV challenge on Vyvanse.

This patent has one hundred and forty-three patent family members in twenty-six countries.

Summary for Patent: ► Subscribe

Title:Abuse-resistant amphetamine prodrugs
Abstract:The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s): Mickle; Travis (Coralville, IA), Krishnan; Suma (Belvedere, CA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Oberlender; Robert (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Paul; Bernhard J. (Lexington, MA), Verbicky; Christopher A. (Broadalbin, NY)
Assignee: Shire LLC (Florence, KY)
Application Number:12/202,096
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-001Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-002Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-003Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-004Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-005Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-006Jan 28, 2017RXYesYes► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-007Oct 30, 2014RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-004Dec 10, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-001Feb 23, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-005Dec 10, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,427,600Active agent delivery systems and methods for protecting and administering active agents► Subscribe
7,671,030Abuse-resistant amphetamine prodrugs► Subscribe
7,622,441Sustained release pharmaceutical compounds to prevent abuse of controlled substances► Subscribe
8,343,927Pharmaceutical compositions for prevention of overdose or abuse► Subscribe
7,662,787Abuse resistant lysine amphetamine compounds► Subscribe
8,394,813Active agent delivery systems and methods for protecting and administering active agents► Subscribe
6,716,452 Active agent delivery systems and methods for protecting and administering active agents► Subscribe
7,163,918Iodothyronine compositions► Subscribe
7,687,466Abuse-resistant amphetamine prodrugs► Subscribe
7,671,031Abuse-resistant amphetamine prodrugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1644019► SubscribeCA 2013 00043Denmark► Subscribe
European Patent Office1644019► Subscribe1390058-4Sweden► Subscribe
European Patent Office1644019► Subscribe122013000079Germany► Subscribe
European Patent Office1675555► Subscribe
European Patent Office1865980► Subscribe
European Patent Office2080511► Subscribe
European Patent Office2266590► Subscribe
European Patent Office2316468► Subscribe
European Patent Office2316469► Subscribe
European Patent Office2319540► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Cantor Fitzgerald
Healthtrust
Accenture
Medtronic
Chubb
US Department of Justice
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot